Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ploeger

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Cancer Chemotherapy and Pharmacology|June 1, 2010
Marginal increase of sunitinib exposure by grapefruit juiceNielka P van Erp, Sharyn D Baker, Anthe S Zandvliet, et al.
Transfusion|January 12, 2013
Lot-to-lot variability in HLA antibody screening using a multiplexed bead-based assayManish J Gandhi, Danielle M Carrick, Sarah Jenkins, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2021
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignanciesBirgit Geoerger, Bruce Morland, Irene Jiménez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2023
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer StudyMichela Casanova, Francisco Bautista, Quentin Campbell-Hewson, et al.
British Journal of Clinical Pharmacology|June 24, 2016
Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipientsDirk Jan A R Moes, Rogier R Press, Oliver Ackaert, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinomaAnthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
Eclinicalmedicine|April 24, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyMarwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Cancer Chemotherapy and Pharmacology|June 1, 2010
Marginal increase of sunitinib exposure by grapefruit juiceNielka P van Erp, Sharyn D Baker, Anthe S Zandvliet, et al.
Transfusion|January 12, 2013
Lot-to-lot variability in HLA antibody screening using a multiplexed bead-based assayManish J Gandhi, Danielle M Carrick, Sarah Jenkins, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2021
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignanciesBirgit Geoerger, Bruce Morland, Irene Jiménez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2023
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer StudyMichela Casanova, Francisco Bautista, Quentin Campbell-Hewson, et al.
British Journal of Clinical Pharmacology|June 24, 2016
Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipientsDirk Jan A R Moes, Rogier R Press, Oliver Ackaert, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinomaAnthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
Eclinicalmedicine|April 24, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyMarwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, et al.
Pageof 7